Back

Global Learning Collaborative

  • Alzheimer Disease

Reimagining Alzheimer’s Care: The Advent of Subcutaneous Administration of Anti-Amyloid Therapy

In this activity, Dr. Alireza Atri and Dr. Scott Turner discuss the evolving role of subcutaneous anti-amyloid monoclonal antibody therapy in early Alzheimer disease. The conversation compares intravenous and subcutaneous administration and focuses on maintenance dosing after 18 months of IV therapy, practical implications for patients and care partners, and the potential impact on infusion-center burden and treatment access. Dr. Dani Cabral then speaks with a patient living with Alzheimer s disease, who shares his perspective on using the subcutaneous formulation in the broader context of disease-modifying treatment and long-term management.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AAPA Category 1 Credit™Up to 0.5 creditsAMA PRA Category 1 Credit™Up to 0.5 creditsNursingUp to 0.5 creditsPharmacyUp to 0.5 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Pricing

Free

Reported to ACCME by the provider

  • Enduring / On-demand
  • Credit · Up to 0.5 credits
  • Commercial Support
  • Released
    Jun 23, 2026
  • Last day to claim credit
    Jun 24, 2027 9 months left